Tissue donations for multiple sclerosis research: current state and suggestions for improvement

Abstract Although major progress in multiple sclerosis research has been made during the last decades, key questions related to the cause and the mechanisms of brain and spinal cord pathology remain unresolved. These cover a broad range of topics, including disease aetiology, antigenic triggers of the immune response inside and/or outside the CNS and mechanisms of inflammation, demyelination neurodegeneration and tissue repair. Most of these questions can be addressed with novel molecular technologies in the injured CNS. Access to brain and spinal cord tissue from multiple sclerosis patients is, therefore, of critical importance. High-quality tissue is provided in part by the existing brain banks. However, material from early and highly active disease stages is limited. An initiative, realized under the patronage of the European Charcot Foundation, gathered together experts from different disciplines to analyse the current state of multiple sclerosis tissues collected post-mortem or as biopsies. Here, we present an account of what material is currently available and where it can be accessed. We also provide recommendations on how tissue donation from patients in early disease stages could be potentially increased and for procedures of tissue sampling and preservation. We also suggest to create a registry of the available tissues that, depending on the source (autopsy versus biopsy), could be made accessible to clinicians and researchers.

[1]  S. Elledge,et al.  Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis , 2022, Science.

[2]  D. Reich,et al.  A lymphocyte–microglia–astrocyte axis in chronic active multiple sclerosis , 2021, Nature.

[3]  G. Sancesario,et al.  Biobanking for Neurodegenerative Diseases: Challenge for Translational Research and Data Privacy , 2021, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[4]  B. Erickson,et al.  Magnetic Resonance Imaging Correlates of Multiple Sclerosis Immunopathological Patterns , 2021, Annals of neurology.

[5]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[6]  T. Kuhlmann,et al.  Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[7]  D. Reich,et al.  Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. , 2020, JAMA neurology.

[8]  H. Lassmann,et al.  Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis , 2020, Acta Neuropathologica.

[9]  T. Kuhlmann,et al.  Lesion stage-dependent causes for impaired remyelination in MS , 2020, Acta Neuropathologica.

[10]  M. Absinta,et al.  Mechanisms underlying progression in multiple sclerosis. , 2020, Current opinion in neurology.

[11]  C. Wegner,et al.  Extensive subpial cortical demyelination is specific to multiple sclerosis , 2020, Brain pathology.

[12]  B. Serafini,et al.  Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism , 2019, Journal of Virology.

[13]  Richard Reynolds,et al.  Neuronal vulnerability and multilineage diversity in multiple sclerosis , 2019, Nature.

[14]  O. Ornatsky,et al.  Multiplexed imaging of immune cells in staged multiple sclerosis lesions by mass cytometry , 2019, bioRxiv.

[15]  Dheeraj Malhotra,et al.  Altered human oligodendrocyte heterogeneity in multiple sclerosis , 2019, Nature.

[16]  E. Remmerswaal,et al.  Tissue-resident memory T cells populate the human brain , 2018, Nature Communications.

[17]  Stephen E. Jones,et al.  Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study , 2018, The Lancet Neurology.

[18]  K. Kitagawa,et al.  CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma , 2018, Multiple sclerosis.

[19]  C. V. van Eden,et al.  Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: a retrospective autopsy cohort analysis , 2018, Acta Neuropathologica.

[20]  H. Lassmann,et al.  Inflammatory demyelinating diseases of the central nervous system , 2017, Handbook of Clinical Neurology.

[21]  H. Algahtani,et al.  Tumefactive demyelinating lesions: A comprehensive review. , 2017, Multiple sclerosis and related disorders.

[22]  H. Lassmann,et al.  Multiple sclerosis: experimental models and reality , 2016, Acta Neuropathologica.

[23]  C. Marini,et al.  Tumefactive demyelinating lesions: spectrum of disease, diagnosis andtreatment , 2016 .

[24]  Hans Lassmann,et al.  An updated histological classification system for multiple sclerosis lesions , 2016, Acta Neuropathologica.

[25]  Istvan Pirko,et al.  Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque , 2015, Annals of neurology.

[26]  S. Weigand,et al.  Pathologic heterogeneity persists in early active multiple sclerosis lesions , 2014, Annals of neurology.

[27]  Ching-Piao Tsai,et al.  Tumefactive Multiple Sclerosis in Taiwan , 2013, PloS one.

[28]  Simon Hametner,et al.  Disease-specific molecular events in cortical multiple sclerosis lesions , 2013, Brain : a journal of neurology.

[29]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[30]  R. Reynolds,et al.  The neuropathological basis of clinical progression in multiple sclerosis , 2011, Acta Neuropathologica.

[31]  桐山 敬生 Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30mm , 2011 .

[32]  C. Kesavadas,et al.  Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event , 2010, Journal of the Neurological Sciences.

[33]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[34]  A. Ascherio,et al.  Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[35]  W. Brück,et al.  Remyelination capacity of the MS brain decreases with disease chronicity , 2009, Neurology.

[36]  W. Brück,et al.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis , 2008, Brain : a journal of neurology.

[37]  Hans Lassmann,et al.  Multiple sclerosis and Alzheimer's disease , 2008, Annals of neurology.

[38]  W. Brück,et al.  Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach , 2008, Acta Neuropathologica.

[39]  Elizabeth Fisher,et al.  Imaging correlates of axonal swelling in chronic multiple sclerosis brains , 2007, Annals of neurology.

[40]  F. Aloisi,et al.  Lymphoid neogenesis in chronic inflammatory diseases , 2006, Nature Reviews Immunology.

[41]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[42]  K. Jellinger,et al.  The significance of perivascular infiltrations in multiple sclerosis , 1975, Journal of Neurology.

[43]  Wolfgang Brück,et al.  Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. , 2002, Brain : a journal of neurology.

[44]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[45]  J. Prineas,et al.  Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. , 1978, Laboratory investigation; a journal of technical methods and pathology.